Kiniksa Pharmaceuticals Ltd (KNSA)vsMerck & Company Inc (MRK)
KNSA
Kiniksa Pharmaceuticals Ltd
$78.20
-3.36%
HEALTHCARE · Cap: $4.81B
MRK
Merck & Company Inc
$129.79
-0.44%
HEALTHCARE · Cap: $307.25B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 8622% more annual revenue ($65.77B vs $754.04M). MRK leads profitability with a 13.6% profit margin vs 9.7%. MRK trades at a lower P/E of 35.6x. KNSA earns a higher WallStSmart Score of 53/100 (C-).
KNSA
Buy53
out of 100
Grade: C-
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+76.7%
Fair Value
$192.76
Current Price
$78.20
$114.56 discount
Margin of Safety
-62.3%
Fair Value
$81.23
Current Price
$129.79
$48.56 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 55.5% year-over-year
Earnings expanding 145.5% YoY
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
Trading at 9.5x book value
Premium valuation, high expectations priced in
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : KNSA
The strongest argument for KNSA centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : KNSA
The primary concerns for KNSA are Price/Book, P/E Ratio. A P/E of 70.3x leaves little room for execution misses.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
KNSA profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
MRK carries more volatility with a beta of 0.20 — expect wider price swings.
KNSA is growing revenue faster at 55.5% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
KNSA scores higher overall (53/100 vs 50/100) and 55.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kiniksa Pharmaceuticals Ltd
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Kiniksa Pharmaceuticals Ltd. (KNSA) is an innovative biopharmaceutical company focused on developing breakthrough therapies to address pressing unmet medical needs, particularly in the realm of autoimmune disorders. Its flagship candidate, KPL-404, is a monoclonal antibody designed to effectively modulate immune responses, positioning Kiniksa at the forefront of promising therapeutic advancements. The company boasts a strong clinical pipeline supported by strategic partnerships that enhance its research and development capabilities. With a dedication to transforming treatment paradigms and a robust growth trajectory, Kiniksa represents an attractive opportunity for institutional investors seeking impactful investments in the evolving healthcare landscape.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?